An Open-label, International, Multicenter, Dose Escalating Phase I/II Trial Investigating the Safety of Daratumumab in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.

Trial Profile

An Open-label, International, Multicenter, Dose Escalating Phase I/II Trial Investigating the Safety of Daratumumab in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 20 Jun 2013

At a glance

  • Drugs Daratumumab (Primary) ; Bortezomib; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Jun 2013 Status changed from recruiting to withdrawn prior to recruitment, as reported by ClinicalTrials.gov.
    • 13 Apr 2013 Additional lead trial centre identified as reported by European Clinical Trials Database.
    • 03 Apr 2013 According to a Genmab media release the US FDA has granted fast track designation for daratumumab in patients with multiple myeloma.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top